
CLAIMS

1. Use of a compound represented by the following structural formula:



(I),

or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a subject with complex karyotype acute myeloid leukemia.

2. The use according to claim 1, wherein the complex karyotype acute myeloid leukemia is relapsed or refractory.

3. The use according to claim 1 or 2, wherein the compound is a fumarate salt.

4. The use according to claim 3, wherein the molar ratio between the compound and fumaric acid is 1:1.

5. The use according to any one of claims 1-4, further comprising co-administering an additional therapeutic agent.

6. The use according to claim 5, wherein the additional therapeutic agent is an anti-cancer drug.

7. The use according to claim 6, wherein the anti-cancer drug is Venetoclax.

8. The use according to claim 6, wherein the anti-cancer drug is 5-Azacytidine.

9. The use according to any one of claims 5-8, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are administered concurrently.

10. The use according to any one of claims 5-8, wherein Compound (I) or a pharmaceutically acceptable salt thereof and the additional therapeutic agent are administered sequentially.